Mayo Clinic to use blockchain technology to trial clinical data design

2 years ago 106
Mayo Clinic Logo

US nonprofit medical center Mayo Clinic is to integrate blockchain technology to embed verifiable clinical data as part of a design trial involving 10 research sites and over 500 patients.

For this project, Mayo Clinic is onboarding Triall, a Dutch-based startup that offers a tokenised platform blockchain-integrated clinical trials, the firms announced on Thursday.

Researchers at the American healthcare firm are working with Triall’s eClinical team on an effort aimed at taking clinical trial design to the next level, with the goal being to help transform decentralised clinical research across the globe.

Advancing clinical data integrity

According to the firms, the trial is set to begin this September, and see Triall’s eClinical platform support a multi-center pulmonary arterial hypertension trial over the next two years. As noted, the trial will involve 10 research sites and more than 500 patients in the US.

Mayo Clinic expected the blockchain startup’s eClinical solutions to support all core aspects of the trial, including data capture, study monitoring, document management, and eConsent.

The collaboration looks to demonstrate the potential for Triall’s Verifiable Proof API to boost clinical data integrity via audit trails that benefit from blockchain immutability.

The collaboration also seeks to explore the potential of a system-independent interface for the medical ecosystem, where researchers, investigators, regulators and other trial stakeholders can access and evaluate integrity of documents and data related to a particular trial.

Triall launched on 7 May 2018, founded by Hadil Es-Sbai, Joost Flach, Linda van de Burgwal, and three others. Its technology brings Web3 to the medical research space, offering software solutions that support secure, transparent and tamper-resistant clinical trials.

The post Mayo Clinic to use blockchain technology to trial clinical data design appeared first on Invezz.

Read Entire Article